BACKGROUND: Ewing's @entity242 , @entity421 , and @entity980 are significantly more responsive to chemotherapy than other @entity242 . Adjuvant chemotherapy is used routinely based on data from randomized trials. Although a percentage of @entity1 with locally advanced or @entity3 remain curable, few data exist regarding the @entity5 's natural history or response and survival in adults. METHODS: This Phase II study evaluated @entity632 , @entity2699 , @entity1260 , and mesna (MAID) in adults with inoperable or metastatic @entity2828 , @entity980 , or @entity421 . RESULTS: Between 1987-1991, 81 @entity1 were entered; 69 @entity1 were eligible. One @entity1 died of @entity281 . Ten @entity1 (14%) responded completely and 34 @entity1 (49%) had a complete or partial response. Response rates were significantly higher for @entity1 with @entity2828 and @entity980 than for those with @entity421 (77%, 64%, and 26%, respectively; P < 0.005). Although there were no significant differences in progression free survival by histology, survival for @entity1 with @entity2828 was significantly longer than for @entity1 with @entity421 (P = 0.004.) At the time of last follow-up, 7 @entity1 (10%) were alive without progression: 3 with @entity2828 , 1 with @entity421 , and 3 with @entity980 . CONCLUSIONS: MAID chemotherapy is an active regimen in adults with advanced or metastatic @entity2828 and @entity980 . Although there was no direct comparison with a @entity632 and @entity900 -based regimen, the response rate and survival in @entity1 with @entity421 suggest that @entity632 and @entity900 -based chemotherapy would remain the accepted initial chemotherapy regimen. For @entity1 with @entity980 and @entity2828 , 10-20% of @entity1 remained disease free at 5 years.

A Southwest Oncology Group and @entity5 and Leukemia Group B phase II study of @entity632 , @entity2699 , @entity1260 , and mesna in adults with advanced XXXX , @entity2828 , and @entity980 .

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity2828 :: ('MESH:D012512', 'Disease') :: ["Ewing's sarcoma"] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas'] @entity2699 :: ('MESH:D003606', 'Chemical') :: ['dacarbazine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity281 :: ('MESH:D007239', 'Disease') :: ['neutropenic infection'] @entity421 :: ('MESH:D012516', 'Disease') :: ['osteosarcomas', 'osteosarcoma'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic tumors'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide'] @entity980 :: ('MESH:D012208', 'Disease') :: ['rhabdomyosarcoma', 'rhabdomyosarcomas']
@entity421 :: (MESH:D012516,Disease) :: ['osteosarcoma']
